



Sequella, Incorporated  
9610 Medical Center Drive  
Suite 200  
Rockville, MD 20850  
Tele: 301-762-7776  
Fax: 301-762-7778

**FOR IMMEDIATE RELEASE**

**SPRINGBOARD: NEW ENGLAND 2001 SELECTS SEQUELLA, INC.  
TO PRESENT AT NOVEMBER VENTURE FORUM FOR WOMEN ENTREPRENEURS**

**October 19, 2001 — Rockville, MD** — The Center for Women & Enterprise, and Springboard Enterprises, today announced that Dr. Carol A. Nancy, CEO of Sequella, Inc., has been selected as one of 23 women entrepreneurs who will present their businesses before the region's top investors at Springboard: New England 2001 Venture Capital Forum. Sequella is one of only three biotech companies that will participate in this event, which takes place on Friday, November 9, at Harvard Business School.

The Springboard Venture Forums are a national initiative that identifies and showcases women entrepreneurs to the investment community. A committee of the region's top venture capitalists and business leaders, including Forum Co-Chairs Bob Higgins of Highland Capital and Myra Hart of Harvard Business School, choose presenting companies. Companies were chosen from a pool of nearly 150 applicants seeking seed, early and later stage funding for their start-up businesses.

Sequella is the only company solely focused on tuberculosis (TB) – the leading single-agent infectious disease killer in the world, leading cause of death for women of childbearing age and people infected with HIV. In the 1990's alone, there were 30 million estimated deaths due to TB, and it is predicted that TB will kill between 70 to 90 million people in the next three decades. According to the World Health Organization and Harvard School of Public Health, approximately \$4 billion is spent every year on TB control, of which \$2.8 billion is spent by developed countries such as the United States. New York City, for example, spent nearly \$1 billion containing an outbreak of multi-drug resistant TB in the early 1990s.

Sequella is poised to capture a large part of the TB market by discovering, developing and commercializing products that can alleviate the global burden of TB. As the former Executive Vice President and Chief Scientific Officer of Entremed (NASDAQ: ENMD), Dr. Carol Nancy has demonstrated her abilities to build Sequella into the market leader in infectious disease treatment.

*MORE*

“Springboard 2001 gives us the opportunity to describe for investors the exciting and innovative technologies we’ve accessed to address a global epidemic that isn’t being properly treated or monitored,” Dr. Nancy said. “Sequella is developing a broad array of products in various developmental stages, ranging from pre-clinical to phase III clinical trials. Our first product is anticipated to be in the marketplace as early as 2003, and one of our discovery products, the TransVax™ TB vaccine, has already been licensed to a European company.”

“The participants selected for this year’s Springboard Forum represent the best talent in the entrepreneurial community,” said Andrea Silbert, CEO of the Center for Women & Enterprise, the host of the Springboard: New England 2001 Forum. “These forums offer talented entrepreneurs ready access to the ‘who’s who’ within the investment community.”

### **About Sequella, Inc.**

Sequella, Inc. is a development stage biotechnology company designed to facilitate the translation of concepts that exist at the lab bench into commercial therapeutics, vaccines, and diagnostics that can alleviate the global burden of infectious disease. The company, headquartered in Rockville, MD, is focusing its initial research efforts on therapeutics, diagnostics and vaccines to address the growing tuberculosis (TB) problem worldwide. For more information about Sequella, Inc., please visit [www.sequella.com](http://www.sequella.com).

### **About Springboard: New England 2001**

Springboard Enterprises, a national non-profit organization to increase women’s participation in equity capital markets, has partnered with the Center for Women & Enterprise, the largest regional entrepreneurial training organization in Massachusetts and Rhode Island, to host the Venture Capital Forum 2001 in New England.

For more information about Springboard: New England 2001, please visit [www.springboard2001.org](http://www.springboard2001.org).

###